NCT00381173View on ClinicalTrials.gov

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Breast CancerOvarian CancerProstate CancerColon CancerRenal Cancer
Interventions
DRUG

Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).

Trial Locations (2)

77030

M. D. Anderson Cancer Center, Houston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00381173 - A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing | Biotech Hunter | Biotech Hunter